日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial

博舒替尼与伊马替尼治疗新诊断的慢性期慢性粒细胞白血病:BELA试验24个月随访结果

Brümmendorf, Tim H; Cortes, Jorge E; de Souza, Cármino Antonio; Guilhot, Francois; Duvillié, Ladan; Pavlov, Dmitri; Gogat, Karïn; Countouriotis, Athena M; Gambacorti-Passerini, Carlo

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

博舒替尼与伊马替尼治疗新诊断的慢性期慢性粒细胞白血病:BELA试验结果

Cortes, Jorge E; Kim, Dong-Wook; Kantarjian, Hagop M; Brümmendorf, Tim H; Dyagil, Irina; Griskevicius, Laimonas; Malhotra, Hemant; Powell, Christine; Gogat, Karïn; Countouriotis, Athena M; Gambacorti-Passerini, Carlo